Huahai Pharmaceutical Gets U.S. FDA Nod For Irbesartan Tablets
This article was originally published in PharmAsia News
Huahai Pharmaceutical said it has won U.S. FDA approval for its generic irbesartan (Avapro) hydrochlorothiazide tablets under an Abbreviated New Drug Application to sell the products in the U.S. market.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.